CLINICAL TRIALS PROFILE FOR GENOSYL
✉ Email this page to a colleague
All Clinical Trials for GENOSYL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01265888 ↗ | Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. | Completed | Geno LLC | Phase 2 | 2011-03-01 | A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo. |
| NCT02436512 ↗ | Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide | Withdrawn | Geno LLC | Phase 3 | 2015-06-01 | The EAGLE study is a Phase 3, open-label, multi-center, two-part, single-arm study of GeNOsyl(R) delivery system(s) to evaluate if inhaled nitric oxide-induced vasodilation predicts successful wean from parenteral prostacyclin (PGI) in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) undergoing a medically necessary right heart catheterization (RHC). All subjects enrolled in the study will undergo an attempt to wean from parenteral PGI per standard of care. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GENOSYL
Condition Name
Clinical Trial Locations for GENOSYL
Trials by Country
Clinical Trial Progress for GENOSYL
Clinical Trial Phase
Clinical Trial Sponsors for GENOSYL
Sponsor Name
